背景:在古巴,没有ST段抬高型心肌梗死(STEMI)的登记,对绩效指标的分析也没有广泛报道。
目的:对古巴STEMI患者的研究进行综述,以描述医疗质量。
方法:Cochrane图书馆,EMBASE,PubMed,Scopus和SciELO,以及国家期刊的档案,都在古巴搜索STEMI的文章,从2000年到2020年3月。如果他们报告了再灌注治疗的应用数量或百分比;阿司匹林的给药,依那普利-卡托普利(ACEI)或β受体阻滞剂;出院时患者的状况;以及患者或系统的延迟时间。最后,包括17例报告,包括7823例患者。
结果:对3991例患者(51%)进行了溶栓治疗,695例(8.9%)死亡。只有四项研究,有880名患者,提供有关ACEI处方的数据,阿司匹林,和β受体阻滞剂,381例(45.3%),824(93.6%),464例(52.7%)患者,分别。在5项研究中报道了冠状动脉介入治疗3422例患者,在661年执行(19.3%)。结论:与类似情况相比,STEMI患者的护理质量似乎较差。溶栓给药仍然很低,虽然死亡率在这一时期有所下降。其他药物治疗没有充分实现。
In Cuba, there is neither a registry of ST Elevation Myocardial Infarction (STEMI), nor are analysis of performance measures widely reported.
A review of Cuban studies of patients with STEMI was carried out to describe quality of medical care.
Cochrane Library, EMBASE, PubMed, Scopus and SciELO, as well as archives of national journals, were all searched for articles on STEMI in Cuba, from 2000 to March 2020. They were included if they reported number or percentage of application of reperfusion therapy; administration of aspirin,
enalapril-captopril (ACEI) or beta-blockers; status of patients at discharge; and patient or system delay times. Finally, 17
reports with 7823 patients were included.
Thrombolytic therapy was administered to 3991 patients (51%), and 695 patients (8.9%) died. Only four studies, with 880 patients, presented data about prescription of ACEI, aspirin, and beta-blockers, which were administered to 381 (45.3%), 824 (93.6%), 464 (52.7%) patients, respectively. Coronary intervention was reported in 5 studies with 3422 patients, being performed in 661 (19.3%). Conclusions: Quality of care of patients with STEMI seems to be poorer than reported in similar scenarios. Thrombolytic administration is still low, although mortality decreases in this period. Other pharmacological treatments were insufficiently fulfilled.